aTYR PHARMA (ATYR) Cash from Financing Activities (2014 - 2026)
aTYR PHARMA's (ATYR) quarterly Cash from Financing Activities came in at -$129000.0 in Q2 2026, down 100.72% on a YoY basis from $17.9 million in Q2 2025, and up 9.15% quarter-over-quarter from -$142000.0 in Q1 2026.
Powered by 
Analysis
aTYR PHARMA (ATYR) Cash from Financing Activities (2014 - 2026) Analysis & Trends
aTYR PHARMA (ATYR) has reported Cash from Financing Activities for 13 consecutive years, with -$129000.0 the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Cash from Financing Activities fell 100.72% year-over-year to -$129000.0; the trailing twelve-month figure through Jun 2026 stood at $29.2 million (down 47.13% YoY), and the FY2025 full-year result was $66.0 million, up 65.59% from the prior year.
- Cash from Financing Activities climbed to -$129000.0 in Q2 2026 per ATYR's latest filing, from -$142000.0 in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $49.5 million in Q1 2023 and bottomed at -$142000.0 in Q1 2026.
- Historically, Cash from Financing Activities has averaged $9.8 million across 5 years, with a median of $4.5 million in 2022.
- The sharpest annual moves came in 2024 and 2025: Cash from Financing Activities slumped 103.91% in 2024, then jumped 28306.67% in 2025.
- Over 5 years, Cash from Financing Activities stood at $918000.0 in 2022, then soared by 557.3% to $6.0 million in 2023, then surged by 212.21% to $18.8 million in 2024, then slumped by 100.7% to -$131000.0 in 2025, then climbed by 1.53% to -$129000.0 in 2026.
- According to Business Quant data, Cash from Financing Activities over the past three periods registered -$129000.0, -$142000.0, and -$131000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 208.48 Bn | 194.49 Bn | 7.24 Bn | -1.48 Bn |
| 2 | Gilead Sciences | 186.29 Bn | 183.02 Bn | 6.22 Bn | 2.34 Bn |
| 3 | Vertex Pharmaceuticals | 128.79 Bn | 120.93 Bn | 2.84 Bn | -426.70 Mn |
| 4 | Regeneron Pharmaceuticals | 80.66 Bn | 72.67 Bn | 3.93 Bn | -1.22 Bn |
| 5 | Moderna | 61.46 Bn | 56.32 Bn | 52.00 Mn | 14.00 Mn |
| 6 | Argenx Se | 61.28 Bn | 56.10 Bn | 1.37 Bn | - |
| 7 | Alnylam Pharmaceuticals | 32.04 Bn | 28.73 Bn | 992.69 Mn | 36.24 Mn |
| 8 | Biogen | 31.84 Bn | 30.56 Bn | 1.96 Bn | 1.30 Bn |
| 9 | Roivant Sciences | 28.74 Bn | 29.43 Bn | 1.16 Mn | -181.51 Mn |
| 10 | aTYR PHARMA | 35.31 Mn | -22.30 Mn | - | -129,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -129,000.00 |
| Mar 31, 2026 | -142,000.00 |
| Dec 31, 2025 | -131,000.00 |
| Sep 30, 2025 | 29.62 Mn |
| Jun 30, 2025 | 17.90 Mn |
| Mar 31, 2025 | 18.63 Mn |
| Dec 31, 2024 | 18.84 Mn |
| Sep 30, 2024 | -105,000.00 |
| Jun 30, 2024 | 13.40 Mn |
| Mar 31, 2024 | 7.73 Mn |
| Dec 31, 2023 | 6.03 Mn |
| Sep 30, 2023 | 2.68 Mn |
| Jun 30, 2023 | 8.02 Mn |
| Mar 31, 2023 | 49.50 Mn |
| Dec 31, 2022 | 918,000.00 |
| Sep 30, 2022 | 3.01 Mn |
| Jun 30, 2022 | 39,000.00 |
| Mar 31, 2022 | 1.48 Mn |
| Dec 31, 2021 | 28,000.00 |
| Sep 30, 2021 | 83.87 Mn |